Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in Northern Chile

Wilderness and Environmental Medicine

Volumn 18, Issue 4, 2007, Pages 251-257

  Moraga, Fernando A ^a   Flores, Alejandro ^a   Serra, Jordi ^a   Esnaola, Carla ^a   Barriento, Corina ^a  

^a UNIVERSIDAD CATÓLICA DEL NORTE   (Chile)

Author keywords

Acute mountain sickness; Ginkgo biloba; High altitude; Lake Louise questionnaire; Prophylaxis

Indexed keywords

ACETAZOLAMIDE; GINKGO BILOBA EXTRACT; PLACEBO;

ADULT; ALTITUDE DISEASE; ARTERIAL OXYGEN SATURATION; ARTERIAL PRESSURE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GINKGO BILOBA; HEART RATE; HUMAN; LAKE LOUISE QUESTIONNAIRE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; OUTCOME ASSESSMENT; OXYGEN SATURATION; QUESTIONNAIRE; SAMPLE SIZE; SCORING SYSTEM; SEA LEVEL; SELF REPORT; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT OUTCOME;

EID: 37449022629     PISSN: 10806032     EISSN: None     Source Type: Journal    
DOI: 10.1580/06-WEME-OR-062R2.1     Document Type: Article

References (31)

1. Gilbert DL. The first documented description of mountain sickness: The Andean or Pariacaca story. Respir Physiol. 1983;52:327-347.
2. Ward MP, Milledge JS, West JB. Acute and subacute mountain sickness. In: High Altitude Medicine and Physiology. London: Chapman & Hall Medical; 1995:366-387.
3. Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976;2:1149-1155.
4. Moraga FA, Osorio J, Vargas M. Acute mountain sickness in children at 3500 m. Wilderness Environ Med. 2002;13:51-54.
5. Vargas M, Osorio J, Jiménez D, Moraga FA, Hudson C, Cortés G. Mal agudo de montana a 3500 y 4250 m: Un estudio de incidencia y severidad de sintomatología. Revísta Médica de Chile. 2001;129:166-172.
6. Swenson ER, Leatham KL, Roach RC, Schoene RB, Mills WJ, Hackett PH. Renal carbonic anhydrase inhibition reduces high altitude sleep periodic breathing. Respir Physiol. 1991;86:333-343.
7. Hackett PH, Roach R. High-altitude illness. N Engl J Med. 2001;345:107-114.
8. Serra J, Barriento C, Esnaola C, Bravo J, Cifuentes F, Moraga FA. Chachacoma ¿Un tratamiento alternativo para la prevención del mal agudo de montaña? Revista Ciencia y Salud. 2001;5:36-42.
9. Galarza M, Peñalosa R, Echalar L, Aguilar M, Spielvoguel H, Sauvain M. Efectos del acullico de coca en la prueba de tolerancia a la glucosa. Medicina. 1997;57:261-264.
10. Bailey DM, Davies B. Acute mountain sickness: prophylactic benefits of antioxidant vitamin supplementation at high altitude. High Alt Med Biol. 2001;2:21-29.
11. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet. 1992;340:1136-1139.
12. Marcocci L, Maguire JJ, Dry-Lefaix MT, Packer L. The nitric oxide-scavenging properties of Ginkgo biloba extract E Ginkgo biloba761. Biochem Biophys Res Commun. 1994;201:748-755.
13. Jowers C, Shih R, James J, Deloughery TG, Holden WE. Effects of Ginkgo biloba on exhaled nitric oxide during normobaric hypoxic in humans. High Alt Med Biol. 2004;54:445-449.
14. Berg JT. Ginkgo biloba extract prevents high altitude pulmonary edema in rats. High Alt Med Biol. 2004;5:429-434.
15. Roncin JP, Scwartz F, D'Arbigny PE. Ginkgo biloba761 in placebo of acute mountain sickness and vascular reactivity to cold exposure. Aviat Space Environ Med. 1996;67:445-452.
16. Gertsch JH, Seto TB, Mor J, Onopa J. Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one days before rapid ascent. High Alt Med Biol. 2002;3:29-37.
17. Gertsch JH, Basnyat B, Johnson EW, Onopa J, Holck PS. Randomised, double blind, placebo controlled comparison of Ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). Br Med J. 2004;328:797-801.
18. Chow T, Browne V, Heileson HK, Wallace F, Anholm J, Green SM. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch Intern Med. 2005;165:296-301.
19. Lake-Louise consensus on the definition and quantification of high altitude illness. In: Sutton JR, Coates G, Houston CS, eds. Hypoxia and Mountain Medicine. Burlington, VT: Queen City Printers Inc; 1992:327-330.
20. West J. Human tolerance to extreme altitudes. In: Leon-Velarde F Arregui A, eds. Hipoxia: Investigaciones Básicas y Clínicas. Lima, IFEA-UPCH; 1993:227-241.
21. Roach RC, Hackett PH. Frontiers of hypoxia research: acute mountain sickness. J Exp Biol. 2001;204:3161-3170.
22. Leadbetter G, Maakestad K, Olson S, Hackett PH. Ginkgo biloba reduces incidence and severity of acute mountain sickness. High Alt Med Biol. 2001;2:110.
23. Van Mil AHM, Spilt A, Van Buchem MA, et al. Nitric oxide mediates hypoxia-induced cerebral vasodilation in humans. J Appl Physiol. 2002;92:962-966.
24. Schilling L, Wahl M. Mediators of cerebral edema. Adv Exp Biol Med. 1999;464:123-141.
25. Mansoor JK, Morrissey BM, Walby WF, et al. L-arginine supplementation enhances exhaled NO, breath condensate VEGF, and headache at 4,342 m. High Alt Med Biol. 2005;6:289-300.
26. Heo HE, Han SW, Lee SK. Free radicals as triggers of brain edema formation after stroke. Free Radic Biol Med. 2005;39:51-70.
27. Bailey DM, Kleger GR, Holzgraefe M, Ballner PE, Bartsch P. Pathophysiological significance of perooxidative stress, neuronal damage, and membrane permeability in acute mountain sickness. J Appl Physiol. 2004;96:1459-1463.
28. Bailey DA, Roukens R, Knauth M, et al. Free radical-mediated damage to barrier function is not associated with altered brain morphology in high-altitude headache. J Cereb Blood Flow Metab. 2005;1-3.
29. Bailey DM, Davies B, Young IS. Intermittent hypoxic training: implications for lipid peroxidation induced by acute normoxic exercise in active men. Clin Sci (Lond). 2001;101:465-475.
30. 2 during prolonged acetazolamide treatment in humans. Am J Physiol. 1990;258:H954-H959.
31. Kiss B, Dallinger S, Findl O, Rainer G, Eichler H, Schmetterer L. Acetazolamide-induced cerebral and ocular vasodilation in human is independent of nitric oxide. Am J Physiol. 1999;276:R1661-R1667.